Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 441 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx se xxx účely xxxxxxxxxxxx xxxxxxxxxxx x vědeckému xxxxxxx xxxx xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx a xxxxx

(Xxxx x xxxxxxxx xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x ohledem xx xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx a balení xxxxx x xxxxx, x xxxxx a xxxxxxx směrnic 67/548/EHS x 1999/45/XX x x změně nařízení (XX) x. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x xxxxx 3 xxxxxxx VI xxxxxxxx (ES) x. 1272/2008 obsahuje xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx xxxxx xx xxxxxxx kritérií xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X uvedeného xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx xxxxx („xxxxxxxx“) xxxx v xxxxxxx x článkem 37 xxxxxxxx (XX) x. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx harmonizované xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx a xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx klasifikací a xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) x těmto xxxxxxx, xxxxx vydal Xxxxx pro xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx, je xxxxxx xxxxxx, aktualizovat xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx látek. Uvedená xxxxxxxxxx výboru RAC xxxx:

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx xxxxxx x xxxxxxx křemíku (x xxxxxxx < 3 μx,xxxxx > 5 μx x xxxxxx xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] stannanu, dioktyl-, xxx(xxxx xxxxxxx) derivátů [2],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—

stanovisko xx dne 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, tetraglymu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx paklobutrazolu (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-terc-butylbenzyl)propionaldehydu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-chlor-o-tolyloxythioacetátu,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx L-(+)-mléčné xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx kyseliny,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [formaldehyd xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, cyklohexyl(hydroxy)diazen-1-oxidu, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, mefentriflukonazolu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-chlor-4-(chlormethyl)-1-[3-trifluormethyl)fenyl]pyrrolidin-2-onu, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx 2-methyl-1,2-benzothiazol-3(2H)-onu, [XXXX],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx ze xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx (XXX), isopropyl [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, výtažku [xxxx xxxxxxxx za studena xx xxxxx xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, xxxxxxxxxxx superkritickým xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx z 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [D4],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx pirimifos-methylu (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko xx xxx 8. června 2018 ohledně azoxystrobinu (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (ISO), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. listopadu 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko ze xxx 14. září 2018 xxxxxxx hymexazolu (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx hexythiazoxu (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxx (XXX), (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethylen-amino)-1,2,4-triazin-3(2H)-onu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx imiprothrinu (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 butanon-oximu, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, hexyl 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx o xxxxx xxxxx (xxxxx XXX 7439–92–1 x xxxxxxxx xxxxx 082–013–00–1 (xxxxx x prášku; [průměr xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), XXX xx xxxx stanovisku ze xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx environmentální xxxxxxxxxxx xx xxxxxxxxx x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx k nižší xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx xxxxxxxxx xxxxx, ke xxxxxxxxxx xxxxxxx výrobě prášku x xxxxxxxx k xxxxx environmentální xxxxxxxxxxx x celistvých a xxxxxxxxxx xxxxx xxxxxx xxxx x existujících xxxxxxxxx v příloze XX xxxx XXX xxxxxxx xxxxx xxxxxxxxx xxxx, xxx xx xxx xx xxxxxxxxx x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Xxxxx xxxx xxxx xxxxxxxxxx xxxx xxxxxxx poznatky, x nichž vyplývá, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxx, xxx ji xxxxxxxxxx xxxxxxxxxx xxxxxx RAC, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxx proto xxxxxx xxxxxxxx do xxxxxxx VI nařízení (XX) č. 1272/2008, xxxxx XXX xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x látku 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (číslo XXX 111-76-2), xxx třídu xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ byly předloženy xxxx xxxxxxx xxxxxxxx, xx xxxxxxx xxxxxxx, xx klasifikace pro xxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx XXX, xxx xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx vhodná. Xxxx xxxxx nebezpečnosti xx xxxxx neměla být x příloze XX xxxxxxxx (XX) č. 1272/2008 xxxxxxx, xxxxx XXX xxxxxx xxx xxxxxxx xxxxxxxxx k xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; všechny xxxxxxx xxxxx xxxxxxxxxxxxx, x kterých xxxxxxxxx xxxxxxxxxx xxxxxx XXX, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx změněno.

(6)

Dodržování xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, x xxxxxxxx xxxxxxxxxxx regulatorních xxxxxxxxx, xxxxxxxxxx ihned, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx na to, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx x směsí xxxxx xxxx revidovaným xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Xxxx doba xx xxxxxx nezbytná x tomu, xxx xxxxxxxxxx xxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx dodržování dalších xxxxxxxx požadavků, které xxxxxxxx v důsledku xxxx provedených xxxxx xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 xxxx. f) xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (3) xxxx xxxxxxxxx xxxxxxxxx x xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx a Xxxx (EU) č. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx xxx xxxxxxxx, xxx xxxxx nová xxxxxxxxxx xxxxxxxx se xxxxxxxxxxx, označování a xxxxxx xxxxxxxxxx dobrovolně xxxxx dnem xxxxxxxxxxxxx xxxxxx nařízení. Xx xx x souladu x xxxxxxxxx podle xx. 61 xxxx. 2 nařízení (ES) x. 1272/2008,

XXXXXXX TOTO XXXXXXXX:

Článek 1

Změny xxxxxxxx (XX) č. 1272/2008

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (ES) č. 1272/2008 se mění x xxxxxxx x xxxxxxxx xxxxxx nařízení.

Článek 2

Vstup x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx xxxx xx vyhlášení x Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx se xxx xxx 1. xxxxxx 2022.

Xxxxxxxx xx druhého xxxxxxxxxxx tohoto článku xxxxx být látky x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x baleny x xxxxxxx x xxxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxxxx nařízení ještě xxxxx xxxx 1. xxxxxx 2022.

Toto nařízení xx xxxxxxx x celém xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. xxxxxx 2020.

Xx Komisi

Ursula XXX XXX LEYEN

předsedkyně

(1)  manaÚř. věst. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx jsou xxxxxxxx na xxxx xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 xx dne 18. prosince 2006

x xxxxxxxxxx, hodnocení, xxxxxxxxxx x omezování xxxxxxxxxx xxxxx, o xxxxxxx Xxxxxxxx agentury xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/ES x x xxxxxxx xxxxxxxx Rady (EHS) x. 793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, směrnice Rady 76/769/XXX x xxxxxxx Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/XX (Xx. xxxx. L 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012 xx xxx 22. května 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx na trh x xxxxxx xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, x. 1).

XXXXXXX

X příloze VI xxxxxxxx (XX) č. 1272/2008 se xxxxxxx 3 x části 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx tříd x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxx. standardních vět x nebezpečnosti

„007-030-00-3

kyselina xxxxxxx …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 mg/l (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Skin Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx křemíku (x průměru &xx; 3 μx, délce &xx; 5 μx x x poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; trimethoxy(vinyl)silan

220-449-8

2768-02-7

Skin Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

XXXX XX 3

XXXX XX 1

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H225

H331

H301

H336

H370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: ATE = 5 mg/l (páry)

orální: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx xxxxxx: od 0,9 xx x xx 6,0 mm; xxxxx částic: od 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Acute Tox. 4

XXXX XX 2

Xxx Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 mg/kg XX

X = 1

X = 1“

„050-031-00-9

dioktylcín-dilaurát; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1B

STOT XX 1

H360D

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Tox. 4

XXXX XX 2

Xxxxxxx Chronic 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: ATE = 500 mg/kg XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 mg/l (xxxxx xxxx mlha)

orální: XXX = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX RE. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 mg/kg XX

X = 10

M = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 mg/kg XX

X = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (ISO);

methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylát

–

317815-83-1

Aquatic Acute 1

Xxxxxxx Chronic 1

X400

X410

XXX09

Xxx

X410

X = 1000

M = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Corr. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Repr. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: ATE = 2,7 mg/l (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Dam. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

STOT XX 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Acute Xxx. 3

STOT XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Xxxxxxx Chronic 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Corr. 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2RS)-2-[4-(4-chlorfenoxy)-2-(trifluormethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;

mefentriflukonazol

–

1417782-03-6

Skin Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Tox. 2

Xxxxx Tox. 3

STOT XX 1

Eye Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: XXX = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Xxx. 2

Xxxxx Tox. 4

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: ATE = 0,16 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

M = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Skin Xxxx. 1X

Xxx Xxx. 1

Skin Xxxx. 1 A

Aquatic Xxxxx 1

Aquatic Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1B

Muta. 1B

STOT XX 1

H350

H340

H372 (periferní xxxxxxx systém)

GHS08

Dgr

H350

H340

H372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-karboxanilid;

penflufen

–

494793-67-8

Carc. 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

H351

GHS08

Wng

H351“

„616-233-00-1

silthiofam (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

H373

H411

GHS08

GHS09

Wng

H373

H411“

„650-057-00-6

Margosa, výtažek [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

X412

X412“

2)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X se xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x kategorií xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy výstražných xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Xxxxx Xxx. 1

Xxxx Corr. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: C ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

H410

M = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Press. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1B

Aquatic Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1B

Acute Xxx. 2

STOT XX 1

Xxxxxxx Chronic 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 D: C ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [DOTE]

239-622-4

15571-58-1

Repr. 1X

XXXX RE 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx systém)

H410“

„082-013-00-1

olověný xxxxxx; [xxxxxx částic &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD H362

H410

Repr. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: ATE = 300 mg/kg XX xxxxxx: XXX = 500 mg/kg XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

azoxystrobin (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Tox. 3

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

M = 10“

„607-314-00-2

ethofumesát (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: XXX = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, nervový xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071

inhalační: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx TH xxxxxx: XXX = 125 xx/xx TH

Skin Xxxx. 1 X; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Acute Tox. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Aquatic Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

pymetrozin (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční směs: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Acute Xxx. 4

Acute Tox. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 550 mg/kg XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Tox. 4

Acute Xxx. 3

XXXX XX 3

XXXX XX 1

XXXX XX 2

Skin Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (krevní xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx TH xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Aquatic Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 xx xxxxxxx.